Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
63 studies found for:    "Germinoma"
Show Display Options
Rank Status Study
1 Recruiting Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma
Condition: Intracranial Germinoma
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Bleomycin;   Radiation: Reduced dose of radiotherapy
2 Recruiting Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
Conditions: Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma
Interventions: Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: carboplatin;   Drug: etoposide;   Drug: ifosfamide
3 Active, not recruiting
Has Results
Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor
Conditions: Brain Tumor;   Central Nervous System Tumor
Interventions: Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Radiation: radiation therapy
4 Recruiting Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
Conditions: Diffuse Intrinsic Pontine Glioma;   PNET;   Ependymoma;   Germinoma;   Medulloblastoma
Intervention:
5 Recruiting Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Conditions: Germ Cell Tumor;   Teratoma;   Choriocarcinoma;   Germinoma;   Mixed Germ Cell Tumor;   Yolk Sac Tumor;   Childhood Teratoma;   Malignant Germ Cell Neoplasm;   Extragonadal Seminoma;   Non-seminomatous Germ Cell Tumor;   Seminoma
Interventions: Drug: paclitaxel;   Drug: ifosfamide;   Drug: cisplatin;   Drug: pegylated G-CSF;   Drug: G-CSF;   Drug: carboplatin;   Drug: etoposide phosphate;   Procedure: stem cell reinfusion
6 Completed Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
Conditions: Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: oxaliplatin;   Drug: fluorouracil;   Drug: leucovorin calcium;   Other: pharmacological study;   Procedure: positron emission tomography;   Procedure: computed tomography
7 Completed Sunitinib in Treating Young Patients With Refractory Solid Tumors
Conditions: Central Nervous System Metastases;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: sunitinib malate;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Other: laboratory biomarker analysis
8 Terminated Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood Infratentorial Ependymoma;   Childhood Medulloepithelioma;   Childhood Mixed Glioma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Gonadotroph Adenoma;   Pituitary Basophilic Adenoma;   Pituitary Chromophobe Adenoma;   Pituitary Eosinophilic Adenoma;   Prolactin Secreting Adenoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Childhood Spinal Cord Neoplasm;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent Pituitary Tumor;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   T-cell Childhood Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   TSH Secreting Adenoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Drug: dexamethasone
9 Completed Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Medulloepithelioma;   Childhood Mixed Glioma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Extra-adrenal Paraganglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Spinal Cord Neoplasm;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions: Drug: vorinostat;   Drug: temozolomide;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
10 Completed Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Conditions: Childhood Burkitt Lymphoma;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Medulloepithelioma;   Childhood Meningioma;   Childhood Mixed Glioma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Childhood Oligodendroglioma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: vorinostat;   Drug: bortezomib;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Completed Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
Conditions: Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Metastatic Childhood Soft Tissue Sarcoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Childhood Visual Pathway Glioma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride;   Other: pharmacological study
12 Completed ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors
Condition: Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas)
Intervention: Drug: Tivantinib (ARQ 197)
13 Completed Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)
Condition: Dysgerminoma
Intervention: Drug: Darbepoetin alfa
14 Active, not recruiting Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer
Conditions: Stage III Ovarian Epithelial Cancer;   Stage III Ovarian Germ Cell Tumor;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor
Interventions: Biological: pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine;   Other: laboratory biomarker analysis
15 Recruiting Retroperitoneal Lymph Node Dissection in Treating Patients With Stage I-IIA Testicular Seminoma
Conditions: Lymphadenopathy;   Stage I Testicular Seminoma;   Stage II Testicular Seminoma
Interventions: Other: Laboratory Biomarker Analysis;   Procedure: Retroperitoneal Lymph Node Dissection
16 Unknown  A Multi-Centre Phase II Study Using Carboplatin AUC-10 for Metastatic Seminoma With IGCCCG Good Prognosis Disease-Therapy Directed by Initial Metabolic Response on PET-CT
Condition: Metastatic Seminoma
Intervention: Drug: Carboplatin AUC-10
17 Recruiting Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma
Condition: Seminoma
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Drug: Cisplatin
18 Recruiting Therapy De-escalation in Seminoma Stage IIA/B
Condition: Seminoma
Interventions: Drug: Carboplatin;   Radiation: Involved node RT
19 Active, not recruiting Proton Radiotherapy for Stage I, IIA, and IIB Seminoma
Condition: Stage I, IIA and IIB Seminoma
Intervention: Radiation: Proton Radiation Therapy
20 Completed Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Conditions: Recurrent Extragonadal Seminoma;   Recurrent Malignant Extragonadal Germ Cell Tumor;   Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Ovarian Germ Cell Tumor;   Stage III Testicular Cancer;   Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor;   Stage IV Extragonadal Seminoma;   Stage IV Ovarian Germ Cell Tumor
Interventions: Drug: Alvocidib Hydrochloride;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.